Murphy Pohlad Asset Management LLC lowered its position in shares of Pfizer (NYSE:PFE) by 3.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 68,913 shares of the biopharmaceutical company’s stock after selling 2,520 shares during the quarter. Pfizer accounts for about 1.6% of Murphy Pohlad Asset Management LLC’s investment portfolio, making the stock its 20th largest position. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $2,496,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Delphi Private Advisors LLC lifted its holdings in Pfizer by 84.3% during the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,600 shares in the last quarter. Americafirst Capital Management LLC purchased a new position in Pfizer during the third quarter valued at approximately $127,000. Oak Point Wealth Management purchased a new position in shares of Pfizer in the fourth quarter worth $165,000. Cerebellum GP LLC purchased a new position in shares of Pfizer in the fourth quarter worth $166,000. Finally, Lipe & Dalton lifted its holdings in shares of Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares in the last quarter. 71.19% of the stock is currently owned by institutional investors and hedge funds.
Shares of PFE opened at $36.33 on Wednesday. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The firm has a market capitalization of $216,208.05, a P/E ratio of 13.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.90. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the business posted $0.47 earnings per share. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. analysts anticipate that Pfizer will post 2.96 EPS for the current year.
In related news, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total value of $1,515,973.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $36,790. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock worth $9,064,785 in the last 90 days. 0.06% of the stock is currently owned by company insiders.
Several equities analysts have recently commented on the stock. Jefferies Group set a $38.00 target price on shares of Pfizer and gave the stock a “hold” rating in a report on Friday, April 13th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, April 12th. Citigroup reissued a “sell” rating on shares of Pfizer in a report on Thursday, April 12th. Berenberg Bank reissued a “neutral” rating and issued a $37.00 target price on shares of Pfizer in a report on Wednesday, April 11th. Finally, Barclays downgraded shares of Pfizer from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $41.00 to $38.00 in a report on Thursday, April 5th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $39.20.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.